Alliance Global Partners Forecasts Tilray FY2025 Earnings

Tilray Inc (NASDAQ:TLRY - Free Report) - Equities researchers at Alliance Global Partners dropped their FY2025 EPS estimates for shares of Tilray in a research note issued on Wednesday, April 9th. Alliance Global Partners analyst A. Grey now forecasts that the company will post earnings per share of ($1.02) for the year, down from their prior estimate of ($0.18). The consensus estimate for Tilray's current full-year earnings is ($0.20) per share.

TLRY has been the subject of a number of other reports. Piper Sandler cut their price target on Tilray from $2.00 to $1.00 and set a "neutral" rating for the company in a report on Wednesday, April 9th. Canaccord Genuity Group increased their price target on shares of Tilray from $2.00 to $3.00 and gave the company a "buy" rating in a report on Monday, January 13th. Finally, Roth Capital restated a "neutral" rating on shares of Tilray in a research report on Monday.

Tilray Stock Performance

NASDAQ:TLRY traded down $0.04 during mid-day trading on Monday, hitting $0.44. 10,800,947 shares of the company's stock traded hands, compared to its average volume of 29,315,614. The firm has a market capitalization of $412.57 million, a price-to-earnings ratio of -1.48 and a beta of 1.88. The firm has a 50 day moving average of $0.69 and a two-hundred day moving average of $1.15. The company has a current ratio of 2.54, a quick ratio of 1.58 and a debt-to-equity ratio of 0.10. Tilray has a 12 month low of $0.44 and a 12 month high of $2.52.

Tilray (NASDAQ:TLRY - Get Free Report) last released its quarterly earnings results on Tuesday, April 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.06). The firm had revenue of $185.78 million for the quarter, compared to the consensus estimate of $213.38 million. Tilray had a negative net margin of 30.95% and a negative return on equity of 4.40%.

Institutional Trading of Tilray

A number of institutional investors and hedge funds have recently modified their holdings of TLRY. Newman Dignan & Sheerar Inc. lifted its position in Tilray by 61.9% in the fourth quarter. Newman Dignan & Sheerar Inc. now owns 26,150 shares of the company's stock worth $35,000 after purchasing an additional 10,000 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Tilray by 55.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 31,875 shares of the company's stock worth $42,000 after acquiring an additional 11,325 shares during the period. NewEdge Advisors LLC boosted its position in shares of Tilray by 92.1% during the 4th quarter. NewEdge Advisors LLC now owns 27,406 shares of the company's stock valued at $36,000 after acquiring an additional 13,136 shares in the last quarter. TD Waterhouse Canada Inc. increased its stake in Tilray by 59.4% in the fourth quarter. TD Waterhouse Canada Inc. now owns 37,009 shares of the company's stock valued at $49,000 after acquiring an additional 13,786 shares during the period. Finally, Schonfeld Strategic Advisors LLC raised its position in Tilray by 68.0% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 35,121 shares of the company's stock worth $47,000 after purchasing an additional 14,221 shares in the last quarter. 9.35% of the stock is currently owned by institutional investors.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.